Allarity Therapeutics, Inc. 8-K

What Happened Allarity Therapeutics, Inc. announced on March 6, 2026 that it closed a $20 million non‑convertible debt financing with Streeterville Capital. The company filed the announcement on Form 8‑K (Item 8.01) and included a press release as Exhibit 99.1.

Key Details

• Financing amount: $20,000,000 in non‑convertible debt.
• Counterparty: Streeterville Capital.
• Closing date: March 6, 2026.
• Disclosure: Announcement filed on Form 8‑K; press release attached as Exhibit 99.1.

Why It Matters This transaction provides Allarity with $20 million of additional capital without issuing equity, so it does not cause immediate shareholder dilution. Because the financing is debt, investors should monitor future disclosures for the financing terms (interest rate, maturity, covenants and repayment schedule), which will affect the company’s cash obligations and leverage. The 8‑K confirms the closing; further details may appear in subsequent filings or company communications.